Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 28 February 2017 | By Zachary Brennan
Sens. Bernie Sanders (D-VT) and several colleagues who previously opposed such a measure, Cory Booker (D-NJ), Bob Casey (D-PA), Martin Heinrich (D-NM), Angus King (I-ME), alongside Reps. Elijah Cummings (D-MD) and Lloyd Doggett (D-TX) on Tuesday revived legislation lingering for more than a decade to allow the importation of medicines from Canada and other countries to help lower US drug prices.
Sanders called the bill "critical" on Tuesday at a press conference, saying the medicines coming in from Canada is 100% safe and will lower costs. But part of the bill would require companies seeking to bring their drugs into the US to register with the US Food and Drug Administration (FDA) and pay a certification fee.
Also, all companies manufacturing the drugs introduced into Canada and other OECD member countries (most of the EU, Australia, Israel, Japan, Korea, Norway and New Zealand, among others) have to be in compliance with FDA's good manufacturing practice regulations.
All previous legislative efforts, dating back to at least 2003, to allow such imports have failed and run into fierce opposition from the pharmaceutical industry and FDA, with previous commissioners saying such imports cannot be guaranteed as safe.
That opposition appeared again on Tuesday when the Partnership for Safe Medicines and nearly 170 industry-backed groups sent a letter to all members of Congress urging them to “stand against efforts that would allow substandard and even dangerous counterfeit medicines to flow freely across U.S. borders.”
Other experts, however, have said there is no indication that Canadian drugs are less safe or effective than US drugs.
And the bill may have a better shot at passage this year than in the past, particularly as more than a dozen Republicans voted in favor of an amendment in January that would allow such imports, and President Donald Trump has said he supports them.
Earlier this month, Sens. Charles Grassley (R-IA), John McCain (R-AZ) and Amy Klobuchar (D-MN) sent a letter to Tom Price, the newly confirmed secretary of the Department of Health and Human Services, calling on him to fast-track the approval of prescription drugs imported from Canada in four different circumstances, including if the price of a drug increases significantly.
Press Release
Tags: Canada pharmaceutical imports, Bernie Sanders, drug costs, Rx import bill
Regulatory Focus newsletters
All the biggest regulatory news and happenings.